Application of sophocarpidine to preparation of medicine for inhibiting neuroinflammation

A technology of neuroinflammation and matrine, which is applied in the application field of matrine in the preparation of anti-neurinflammation drugs, can solve the problems of complex pathogenesis, special site, and lack of therapeutic drugs in ND, and achieve high clinical application value and development Prospect, effect of inhibiting neuroinflammatory activity

Inactive Publication Date: 2018-05-01
NINGXIA MEDICAL UNIV
View PDF0 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Due to the complex pathogenesis and special location of ND, there is still a lack of effective therapeutic drugs.
However, there is no report about the inhibition of neuroinflammation by matrine

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of sophocarpidine to preparation of medicine for inhibiting neuroinflammation
  • Application of sophocarpidine to preparation of medicine for inhibiting neuroinflammation
  • Application of sophocarpidine to preparation of medicine for inhibiting neuroinflammation

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0029] DCFH oxidation method was used to investigate the effect of matrine on the release of reactive oxygen species (ROS) from microglial cells induced by LPS;

[0030] Cell line: mouse microglial cell line BV-2;

[0031] Drugs: LPS; matrine; MINO.

[0032] Experimental principle: DCFH-DA (2′,7′-dichlorodihydrofluororescein diacetate) can enter the cell and undergo a deacetylation reaction to generate DCFH. DCFH is a non-fluorescent substance, which can be oxidized by intracellular ROS to generate fluorescent substance DCF, and the amount of ROS release can be reflected by detecting the fluorescence intensity. The specific operation steps are as follows: DCFH-DA was dissolved in pure methanol to prepare a mother solution with a concentration of 10 mM, and the mother solution was diluted 500 times with Hank's balanced salt solution (HBSS) to a final concentration of 20 μM before use. Take the BV-2 cells after drug treatment, suck the supernatant, incubate with the 20 μM DCFH...

Embodiment 2

[0036] Effect of matrine on LPS-induced microglial interleukin-6 (IL-6) and prostaglandin E by ELISA 2 (PGE 2 ) release effects;

[0037] Cell line: mouse microglial cell line BV-2;

[0038] Drugs: LPS; matrine; MINO.

[0039] Detection method: Take BV-2 cells in the logarithmic growth phase, inoculate the cells in a 6-well plate with fresh serum-free DMEM medium, and the cell density is 3×10 5 cells / ml, inoculum volume 600μl / well, placed in an incubator at 37°C, 5% CO 2 cultivated under conditions. After the cells adhered to the wall for 3 hours, the culture solution was carefully sucked out, and according to the experimental group, the cells were replaced with different drugs prepared in serum-free DMEM culture solution to incubate the cells. At the same time, a blank control group was set up, and each group was set with 3 replicate wells, and the drug addition to the cells continued. After culturing for 2-4 hours, collect the supernatant, and detect IL-6 and PGE in the...

Embodiment 3

[0043] Iba-1 immunohistochemical staining to investigate the effect of matrine on the activation of microglial cells in the mouse brain induced by LPS;

[0044] Animals: C57BL / 6 mice;

[0045] Drugs: matrine, donepezil, LPS;

[0046] Experimental method: 72 C57BL / 6 mice were randomly divided into 6 groups: normal control group, model control (Aβ) group, matrine high, medium and low dose groups (40, 20, 10mg / kg) and positive drug Donepezil hydrochloride 5mg / kg group. Animals in each group were lightly anesthetized with chloral hydrate and fixed their heads. The skin on the surface of the skull was disinfected with 75% ethanol. The lateral ventricle was positioned 1 mm to the right of the midpoint of the line connecting the two eyes and 2 mm behind the line connecting the posterior corners of the eyes. 2 mm into a sterile micro-syringe, and then slowly inject LPS solution (1 mg / ml, 3 μl / rat), and the normal control group is injected with an equal volume of normal saline. From...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to application of sophocarpidine to inhibition of neuroinflammation and prevention and/or treatment of acute and chronic neurodegenerative diseases caused by the neuroinflammation, in particular to application of sophocarpidine to preparation of medicine for inhibiting neuroinflammation. Pharmacological experiments prove that the sophocarpidine has remarkable inhibition activity of the neuroinflammation and can be used for preparing medicines for preventing and/or treating neuroinflammation and related diseases, so that relatively high clinical application value and development prospect are achieved. The invention discloses application of the sophocarpidine to inhibition of neuroinflammation; furthermore, the pharmacological experiments prove that the sophocarpidine can remarkably inhibit release of LPS induced microglial cell inflammation mediums ROS, IL-6 and PGE2, can remarkably inhibit LPS induced mouse brain microglial cell activation and has the remarkable inhibition activity on the neuroinflammation. Therefore, the compound can be used for preparing the medicines for preventing and/or treating neuroinflammation and related diseases.

Description

technical field [0001] The present invention relates to the application of matrine in inhibiting neuroinflammation and preventing and / or treating acute and chronic neurodegenerative diseases caused by neuroinflammation, especially the application of matrine in the preparation of neuroinflammation-inhibiting drugs. Background technique [0002] Neurodegenerative diseases (neurodegeneration disorders, ND) are a group of chronic progressive neurological diseases based on primary neuron degeneration, mainly including Alzheimer's disease (Alzheimer's disease, AD), Parkinson's disease (Parkinson's disease) , PD), multiple sclerosis (multiple sclerosis, MS), Huntington's disease (Huntington's disease, HD) and so on. With the aging of the world's population, the incidence of neurodegenerative diseases is on the rise. For example, the prevalence of AD in people over 60 years old in my country is 5.1%, and that in people over 85 years old is 30%. There are more than 8 million people, ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/4375A61P25/16A61P25/00A61P25/14A61P25/28
CPCA61K31/4375
Inventor 李娟姚遥刘婷李玮琦
Owner NINGXIA MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap